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Abstract
Background: Colorectal cancer (CRC) is 3rd most commonly diagnosed cancer in males and the second in females.
PD-1/PD-L1 axis, as an immune checkpoint, is up-regulated in many tumors and their microenvironment. However,
the prognostic value of PD-1/PD-L1 in CRC remains unclear.
Methods: The Cancer Genome Atlas (TCGA) database (N = 356) and Fudan University Shanghai Cancer Center
(FUSCC) cohort of patients (N = 276) were adopted to analyze the prognostic value of PD-L1 in colorectal tumor
cells (TCs) and of PD-1 in tumor infiltrating cells (TILs) for CRC. Subgroup analyses were conducted in FUSCC cohort
according to patients’ status of mismatch repair.
Results: In TCGA cohort, the cut-off values of PD-1 and PD-L1 expression were determined by X-tile program,
which were 4.40 and 2.92, respectively. Kaplan-Meier analysis indicated that higher PD-1 and PD-L1 expressions
correlated with better OS (P = 0.032 and P = 0.002, respectively). In FUSCC cohort, expressions of PD-1 on TILs and
PD-L1 on TCs were analyzed separately by immunohistochemistry (IHC) staining based on a TMA sample (N = 276)
and revealed that both TILs-PD-1 and TCs-PD-L1 were associated with OS (P = 0.006 and P = 0.002, respectively)
and DFS (P = 0.025 and P = 0.004, respectively) of CRC patients. Multivariate Cox regression analysis indicated TILs-
PD-1 was an independent prognostic factor both for OS and DFS of CRC patients (P < 0.05). Subgroup analyses
showed that TILs-PD-1 was an independent prognostic factor for both OS and DFS in CRC patients in MSS-
proficient subgroup (P < 0.05), while neither of them correlated with OS or DFS in MSS-deficient subgroup (P > 0.05).
Conclusions: Higher expressions of PD-1 and PD-L1 correlates with better prognosis of CRC patients. TILs-PD-1 is
an independent prognostic factor for OS and DFS of CRC patients, especially for MMR-proficient subgroup.
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Background
Colorectal cancer (CRC) is the third most commonly
diagnosed cancer in males and the second in females,
accounting for approximately 9.7 % of total cancer cases
and approximately 8.5 % of cancer deaths [1]. A consid-
erable proportion of CRC patients develop local recur-
rence and distant metastasis within 5 years after surgical
treatment. Immunotherapy has reached center stage in
the field of second-line therapy in oncology treatment,
and anti-PD-1 therapy has shown objective responses in
variety of human malignancies, including melanoma,
non-small cell lung cancer and renal cell carcinoma [2].
However, only microsatellite instable (MSI) subset of
CRC seems to be a good candidate for checkpoint
blockage immunotherapy [3] and the mechanisms are
still controversial.
Tumor-infiltrating lymphocytes (TILs) are widely con-
sidered as reflection of primary host immune response
against solid tumors. Evidence has shown that tumor in-
filtration by activated CD8+ cytotoxic T lymphocytes
correlates with better survival of CRC patients [4]. PD-
1/PD-L1 axis, as an immune checkpoint, is up-regulated
in many tumors and their microenvironment, and is a
negative feedback system that represses Th1 cytotoxic
immune responses [5]. The engagement of PD-1 by its
ligands (PD-L1 and PD-L2) induces down-regulation of
antigen-stimulated lymphocyte proliferation and cyto-
kine (such as IFN-γ and IL-2) production, resulting in
lymphocyte deletion and in the induction of immuno-
logical tolerance [3, 6–8]. Compared to PD-L2, which
can be detected only in activated dendritic cells (DC)
and macrophages, PD-L1 is constitutively expressed by
T and B cells, DC and macrophages [7, 8], and it is also
expressed in additional cell types, such as endothelial,
pancreatic and muscle cells [9].
The expression of PD-L1 in tumor cells (TCs) has been
validated as a predictive marker for tumor response to anti-
PD-1 or PD-L1 immunotherapy in different malignancies
[2, 10–12]. However, the prognostic value of PD-1 and PD-
L1 expression in different cancers are still controversial. In
the present study, we used 356 cases in The Cancer
Genome Atlas (TCGA) database and a tissue microarray
(TMA) including 276 well-documented, clinically anno-
tated CRC specimens in Fudan University Shanghai Cancer
Center (FUSCC) to investigate the expression of PD-1 and
PD-L1 in CRC and their clinical significance.
Methods
The cancer genome atlas (TCGA) database
PD-1 and PD-L1 expression in patients of CRC and
clinical data of TCGA database are available from the
website of Cancer Genomics Browser of University of
California Santa Cruz (https://genome-cancer.ucsc.edu/).
In total, 356 primary CRC tumors from patients with
detailed PD-1 and PD-L1 expression data were chosen
from the updated TCGA database according to parame-
ters defined in a previous study [13]. Only patients with
fully characterized tumors, intact overall survival (OS),
complete RNAseq information, and patients without
pretreatment were included. Clinicopathological charac-
teristics, including age, gender, tumor location, historical
type, TNM stage, venous invasion, extent of TILs,
microsatellite (MS) status, pretreatment CEA and overall
survival were collected.
Tissue microarray (TMA) construction and
clinicopathological features
The TMA used for this study includes 276 unselected,
non-consecutive, primary, and sporadic CRCs treated
between January 2007 and November 2009 in Fudan
University Shanghai Cancer Center (FUSCC). Construc-
tion of this TMA has been previously described in detail
[14]. Briefly, formalin-fixed, paraffin-embedded tissue
blocks from resected CRC were obtained. Tissue cylinders
with a 0.6 mm diameter were punched from representative
tissue areas of each donor tissue block and brought into
one recipient paraffin block (30 × 25 mm). Each TMA spot
included at least 50 % tumor cells. The histological types
were confirmed by experienced pathologists.
Patients’ demographic and clinicopathological variables,
including age, sex, primary site, histological type, TNM
stage, pathological grade, venous/nervous invasion, regional
lymph node retrieval, MMS status, pretreatment CEA level,
treatment type et al., were retrieved from the FUSCC
database. All patients were restaged according to the 7th
edition of the TNM-UICC/AJCC classification. Venous/
nervous invasion was identified by experienced pathologists
using hemotoxylin/eosin (HE) staining. The regimens used
varied because of long duration of data collection. So, we
simply classify patients into two groups according to
whether patients had received adjuvant chemotherapy or
not. Patients were followed up regularly according to
NCCN guidelines. Physical examination and serum tumor
biomarkers, including CEA, were performed every 3 to
6 months for the first 2 years, 6 months within the third to
fifth year, then annually. Chest/abdominal/pelvis CTs were
performed annually for up to 5 years, and colonoscopy was
performed 1st year after treatment and repeated in 3rd year
if no advanced adenoma was found and then every 5 years.
As this study described the prognosis of patients with CRC,
analysis of OS and DFS were ascertained. The OS was
defined as the time from treatment to death from any
cause, and the DFS was defined as the time from treatment
to the first recurrence or death. The survival data was
provided by Clinical Statistics Center of FUSCC, relying on
the hospital medical records follow-up platform or contacts
with patients by phone or email. Patients who were alive at
last follow-up were censored for analysis.
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Immunohistochemistry (IHC)
Immunohistochemical (IHC) staining was performed ac-
cording to standard protocol. Briefly, paraffin-embedded
samples were cut into 4 μm sections and placed on
polylysine-coated slides. Paraffin sections were baked
overnight at 58 °C, de-paraffinized in xylene, rehydrated
through graded ethanol, quenched for endogenous
peroxidase activity in 0.3 % hydrogen peroxide at 37 °C
for 15 min, and processed for antigen retrieval by high
pressure cooking in citrate antigen retrieval solution (pH
= 6.0) for about 10 min for PD-L1 and EDTA antigen
retrieval solution (pH = 8.0) for about 4 min for PD-1.
Sections were incubated at 37 °C for 1.5 h with rabbit
monoclonal antibodies against PD-1 (1:100, ab137132,
Abcam, Cambridge, MA, USA) and PD-L1 (1:50,
ab174838, Abcam, Cambridge, MA, USA) in a moist
chamber. Immunostaining was performed using the EnVi-
sion+System-HRP (AEC) (K4005, Dako, Glostrup,
Denmark), which resulted in a brown-colored precipitate
at the antigen site. Subsequently, sections were counter-
stained with hematoxylin (Sigma-Aldrich, St Louis, MO,
USA) and mounted in a non-aqueous mounting medium.
All runs included a no primary antibody control.
Evaluation of PD-1 and PD-L1 expression TCs and TILs in
FUSCC cohort
The immunohistochemically stained tissue sections were
scored separately by two pathologists blinded to the
clinicopathological parameters. The staining intensity was
scored as 0 (negative), 1 (weak), 2 (medium) or 3 (strong).
Extent of staining was scored as 0 (<5 %), 1(5–25 %), 2
(26–50 %), 3 (51–75 %) and 4 (>75 %) according to the per-
centages of the positive staining areas in relation to the
whole carcinoma area. Scores for staining intensity and per-
centage positivity of cells were then multiplied to generate
the immunoreactivity score (IRS) for each case. Samples
having a final staining score of ≤ 4 were considered to be
low and those with score of > 4 were considered to be high.
The extent of TILs was assessed in HE stained TMA
preparations using a 4-degree scale on the visual estima-
tion and recorded as 0 (absent), 1 (<30 %), 2 (30 %–
60 %) and 3 (>60 %). Samples with a score of 0 or 1 were
considered negative and those with a score of 2 or 3
were considered positive. The expression of PD-1 in
TILs by IHC method was evaluated using IRS men-
tioned above.
Microsatellite (MS) status and mismatch repair (MMR) status
In the TCGA cohort, MSI was evaluated by exome se-
quence analysis [15]. Based on the assay, 243 CRCs in
the TCGA cohort could be classified as MSS and 113 as
MSI. In the FUSCC cohort, CRCs were stratified accord-
ing to DNA mismatch repair (MMR) status as described
elsewhere [16, 17]. Briefly, MMR-proficient tumors were
defined as those simultaneously expressing MutL homo-
log 1 (MLH1), MutS homolog 2 (MSH2) and MutS
homolog 6 (MSH6), while MMR-deficient tumors were
defined as those lacking expression of at least one of
these markers. Based on these features, 176 CRCs in
FUSCC cohort could be classified as MMR-proficient
and 100 as MMR-deficient.
Statistical analysis
Statistical evaluation was conducted with SPSS 22.0
(SPSS Inc., Chicago, IL, USA) and GraphPad Prism v.6
(La Jolla, CA, USA). X-tile 3.6.1 software [18] (Yale
University, New Haven, CT, USA) was used to deter-
mine the optimal cut-off values for PD-1 and PD-L1
expression in TCGA cohort. Chi-square test was used to
analyze the relationship between clinicopathological
parameters and PD-l, PD-L1 expressions. Survival ana-
lysis was performed using the Kaplan-Meier method and
Cox regression model. P < 0.05 was considered statisti-
cally significant. All confidence intervals (CIs) were
stated at the 95 % confidence level.
Results
Clinical characteristics of patients with CRC in TCGA
cohort and FUSCC cohort
In the TCGA cohort, the median age of all 356 CRC
patients was 66, ranging from 31 to 90 years old. 199
(55.9 %) were male patients and 157 (44.1 %) were female
patients. The median follow-up time was 13.4 months and
68 patients died during follow-up. In the FUSCC cohort,
the median age of 276 CRC patients was 57, ranging from
27 to 85 years old. 166 (60.1 %) were male and 110 (39.9 %)
were female. The median follow-up time was 61.0 months
and 81 patients died during follow-up. Tumor primary site,
histological type, TNM stage, pathological grading, venous/
nervous invasion, extent of TILs, MS/MMR status,
pretreatment CEA level and adjuvant therapy in TCGA
and FUSCC cohorts are shown in Table 1. In the cohort of
TCGA, PD-1 expression was associated with primary site,
TILs extent and MS status (P < 0.05), whereas PD-L1
expression was correlated with venous invasion, TILs
extent, MS status and pretreatment CEA level (P < 0.05). In
the FUSCC cohort, PD-1 expression in TILs was only asso-
ciated with M stage (P < 0.05), whereas PD-L1 expression
in TCs was correlated with T stage and M stage (P < 0.05).
Expression pattern of PD-1 and PD-L1
In the TCGA cohort, the cut-off values of PD-1 and PD-
L1 mRNA levels in tumor tissue of eligible patients were
determined by X-tile program, which were 4.40 and
2.92, respectively (Fig. 1). The χ2 log-rank value of PD-1
and PD-L1 were 4.591 and 9.349, respectively. Patients
were divided into 2 groups for further analysis (PD-1 ≤
4.40 and >4.40, PD-L1 ≤ 2.92 and >2.92).
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Table 1 Comparison of baseline clinicopathological characteristics based on PD-1 and PD-L1 expression of CRC patients in TCGA and FUSCC cohorts
TCGA Cohort (N = 356) FUSCC Cohort (N = 276)
Cases PD-1 Pa PD-L1 Pa Cases PD-1 Pa PD-L1 Pa
No. (%) Low High Low High No. (%) Low High Low High
Age (years)
≤ 60 137 (38.5) 68 (41.2) 69 (36.1) 0.325 21 (38.2) 116 (38.5) 0.960 170 (61.6) 100 (58.8) 70 (66.0) 0.231 85 (61.6) 85 (61.6) 1.000
> 60 219 (35.7) 97 (58.8) 122 (63.9) 34 (61.8) 185 (61.5) 106 (8.4) 70 (41.7) 36 (34.0) 53 (38.4) 53 (38.4)
Gender
Male 199 (55.9) 91 (55.2) 108 (56.5) 0.792 33 (60.0) 166 (55.1) 0.505 166 (60.1) 102 (60.0) 64 (60.4) 0.950 88 (63.8) 78 (56.5) 0.219
Female 157 (44.1) 74 (44.8) 83 (43.5) 22 (40.0) 135 (44.9) 110 (39.9) 68 (40.0) 42 (39.6) 50 (36.2) 60 (43.5)
Primary site
Colon 269 (75.6) 115 (69.7) 154 (80.6) 0.017 46 (83.6) 223 (74.1) 0.130 129 (46.7) 84 (49.4) 45 (42.5) 0.260 65 (47.1) 64 (46.4) 0.904
Rectum 87 (24.4) 50 (30.3) 37 (19.4) 9 (16.4) 78 (25.9) 147 (53.3) 86 (50.6) 61 (57.5) 73 (52.9) 74 (53.6)
Histological type
Adenocarcinoma 316 (88.8) 149 (90.3) 167 (87.4) 0.393 50 (90.9) 266 (88.4) 0.584 261 (94.6) 158 (92.9) 103 (97.2) 0.132 132 (95.6) 129 (93.5) 0.426
Mucinous/SRCC 40 (11.2) 16 (9.7) 24 (12.6) 5 (9.1) 35 (11.6) 15 (5.4) 12 (7.1) 3 (2.8) 6 (4.3) 9 (6.5)
T stage
Tis-T2 68 (19.1) 29 (17.6) 39 (20.4) 0.386 9 (16.4) 78 (25.9) 0.844 43 (15.6) 24 (14.1) 19 (17.9) 0.588 19 (13.8) 24 (17.4) 0.044
T3 242 (68.0) 118 (71.5) 124 (64.9) 39 (70.9) 203 (67.4) 32 (19.6) 32 (18.8) 22 (20.8) 20 (14.5) 34 (24.6)
T4 46 (12.9) 18 (10.9) 28 (14.7) 7 (12.7) 39 (13.0) 179 (64.8) 114 (67.1) 65 (61.3) 99 (71.7) 80 (58.0)
N stage
N0 194 (54.5) 83 (50.3) 111 (58.1) 0.185 23 (41.8) 171 (56.8) 0.101 120 (43.5) 70 (41.2) 50 (47.2) 0.432 57 (41.3) 63 (45.7) 0.767
N1 98 (27.5) 53 (32.1) 45 (23.6) 18 (32.7) 80 (26.6) 83 (30.1) 49 (28.8) 33 (31.1) 43 (31.2) 40 (29.0)
N2 64 (18.0) 29 (17.6) 35 (18.3) 14 (25.5) 50 (16.6) 73 (26.4) 50 (29.4) 23 (21.7) 38 (27.5) 35 (25.4)
M stage
M0 245 (68.8) 109 (66.1) 136 (71.2) 0.107 34 (61.8) 211 (70.1) 0.284 234(84.8) 137 (80.6) 97 (91.5) 0.01 108(78.3) 126 (91.3) 0.003
M1 48 (13.5) 29 (17.6) 19 (9.9) 11 (20.0) 37 (12.3) 42(15.2) 33 (19.4) 9 (8.5) 30(21.7) 12 (8.7)
Mx 63 (17.7) 27 (16.4) 36 (18.8) 10 (18.2) 53 (17.6)
Pathological grading
Well/moderate NA 204(73.9) 67 (73.6) 137 (74.1) 0.498 102(73.9) 102 (73.9) 1.000
Poor/anaplastic 56(20.3) 18 (19.8) 38 (20.5) 28(20.3) 28 (20.3)
Unknown 16(5.8) 6 (6.6) 10 (5.4) 8(5.8) 8 (5.8)
Venous invasion
Negative 235 (66.0) 105 (63.6) 130 (68.1) 0.557 28 (50.9) 207 (68.8) 0.026 184(66.7) 107 (62.9) 77 (72.6) 0.104 85(61.6) 99 (71.7) 0.193
Positive 70 (19.7) 33 (20.0) 37 (19.4) 14 (25.5) 56 (18.6) 88(31.9) 59 (34.7) 29 (27.4) 51(37.0) 37 (26.8)










Table 1 Comparison of baseline clinicopathological characteristics based on PD-1 and PD-L1 expression of CRC patients in TCGA and FUSCC cohorts (Continued)
Nervous invasion
Negative NA 231 (83.7) 75 (82.4) 156 (84.3) 0.181 118 (85.5) 231 (83.7) 0.337
Positive 45 (16.3) 16 (17.6) 29 (15.7) 20 (14.5) 45 (16.3)
TILs extent
Low 47 (13.2) 33 (20.0) 14 (7.3) 0.002 16 (29.1) 31 (10.3) <0.001 129 (46.7) 85 (50.0) 44 (41.5) 0.169 59 (42.8) 70 (50.7) 0.184
High 93 (26.1) 42 (25.5) 51 (26.3) 17 (30.9) 76 (25.2) 147 (53.3) 85 (50.0) 62 (58.5) 79 (57.2) 68 (49.3)
Unknown 216 (60.7) 90 (54.5) 126 (66.0) 22 (40.0) 194 (64.5)
No. of LNs dissected
< 12 80 (22.5) 42 (25.5) 38 (19.9) 0.219 14 (25.5) 56 (18.6) 0.658 39 (14.1) 24 (14.1) 15 (14.2) 0.994 16 (11.6) 23 (16.7) 0.226
≥ 12 247 (69.4) 107(64.8) 140 (73.3) 38 (69.1) 209 (69.4) 237 (85.9) 146 (85.9) 91 (85.8) 122 (88.4) 115 (83.3)
Unknown 29 (8.1) 16 (9.7) 13 (6.8) 3 (5.5) 26 (8.6)
MS status/MMR status
MSS/MMR-proficient 243 (68.3) 123 (74.5) 120 (62.8) 0.018 39 (70.9) 204 (67.8) 0.646 176 (63.8) 102 (60.0) 74 (69.8) 0.099 93 (67.4) 83 (60.1) 0.21
MSI/MMR-deficient 113 (31.7) 42 (25.5) 71 (37.2) 16 (29.1) 97 (32.2) 100 (36.2) 68 (40.0) 32 (30.2) 45 (32.6) 55 (39.9)
CEA (μl/ml)
≤ 5 144 (40.4) 59 (35.8) 85 (44.5) 0.151 13 (23.6) 131 (43.5) 0.007 170 (61.6) 106 (62.4) 64 (60.4) 0.532 80 (58.0) 90 (65.2) 0.382
> 5 85 (23.9) 39 (23.6) 46 (24.1) 13 (23.6) 72 (23.9) 95 (34.4) 59 (34.7) 36 (34.0) 51 (37.0) 44 (31.9)
Unknown 127 (35.7) 67 (40.6) 60 (31.4) 29 (52.7) 98 (32.6) 11 (4.0) 5 (2.9) 6 (5.7) 7 (5.1) 4 (2.9)
Adjuvant chemotherapy
Yes NA 189 (68.5) 58 (63.7) 131 (70.8) 0.082 89 (64.5) 100 (72.5) 0.05
No 49 (17.8) 15 (16.5) 34 (18.4) 23 (16.7) 26 (18.8)
Unknown 38 (13.7) 18 (19.8) 20 (10.8) 26 (18.8) 12 (8.7)










In the FUSCC cohort, the expressions of PD-1 in TILs
and PD-L1 in tumor cells (TCs) were detected by IHC
staining. PD-L1 showed a membrane-accentuated expres-
sion, while PD-1 also displayed a membrane-accentuated
expression, which was often accompanied by a cytoplas-
mic expression (Fig. 2). For further analysis, patients were
divided into two groups with low expression of PD-1/PD-
L1 (IRS ≤ 4) and high expression of them (IRS > 4). In 106
CRC patients (38.4 %), a high expression of PD-1 in TILs
was observed and in 170 cases (61.6 %), PD-1 expression
in TILs was low. While half of the cases in this cohort
displayed a high expression of PD-L1 in TCs, and the
other half showed a low expression of it.
Prognostic significance of PD-1 and PD-L1 expression
In the TCGA cohort, the univariate Cox regression
model revealed that TNM stages, venous invasion,
pretreatment CEA level, PD-1 and PD-L1 expressions
were associated with prognosis of CRC patients in terms
of OS (P < 0.05, Table 2). Multivariate analysis after
adjustment indicated that only T stage and pretreatment
CEA level were independent prognostic factors for OS
in CRC patients (P < 0.05) and PD-1 and PD-L1 expres-
sion lost their significance (P > 0.05).
In the FUSCC cohort, Kaplan-Meier analysis showed that
both the expression of PD-1 in TILs and the expression of
PD-L1 in TCs were associated with OS and DFS of CRC pa-
tients (P < 0.05, Fig. 3a–d). The univariate Cox regression
model indicated that TNM stages, venous invasion, pretreat-
ment CEA level, adjuvant chemotherapy, TILs-PD-1 and
TCs-PD-L1 expressions were correlated with OS (P < 0.05),
whereas TNM stages, venous invasion, nervous invasion,
pretreatment CEA level, adjuvant chemotherapy, TILs-PD-1
and TCs-PD-L1 expressions were associated with DFS.
Multivariate analysis after adjustment revealed that T stage,
M stage, pretreatment CEA level, adjuvant chemotherapy
Fig. 1 Determination of cut-off values of PD-1 and PD-L1 expressions in TCGA database and survival analyses. X-tile analysis of 5-year OS was performed
using patients’ data in TCGA database to determine the optimal cut-off value for PD-1 and PD-L1 expression. The sample of CRC patients was equally
divided into training and validation sets. X-tile plots of training sets are shown in the left panels, with plots of matched validation sets shown in the smaller
inset. The optimal cut-off values highlighted by the black circles in left panels are shown in histograms of the entire cohort (middle panels), and Kaplan-Meier
plots are displayed in right panels. P values were determined by using the cut-off values defined in training sets and applying them to validation sets.
a The optimal cut-off value for PD-1 was 4.40 (χ2 = 4.591, P= 0.032). b The optimal cut-off value for PD-L1 was 2.92 (χ2 = 9.349, P= 0.002)
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and TILs-PD-1 were independent prognostic factors for OS,
while only T stage, M stage and TILs-PD-1 were independ-
ent prognostic factor for DFS of CRC patients (Table 3).
Subgroup analyses of TILs-PD-1 and TCs-PD-L1 expression
according to MMR status in FUSCC cohort
Previous studies indicated that active immune microenvir-
onment was observed in MSI/MMR-deficient tumors [19],
which may lead to a better prognosis of CRC patients. And
it was reported that only microsatellite instable (MSI) subset
of CRC seems to be a good candidate for checkpoint block-
age immunotherapy [3] and the mechanisms are still
controversial. Thus, we further made subgroup analyses of
PD-1 and PD-L1 expressions according to patients’ MMR
status in FUSCC cohort. Kaplan-Meier analysis indicated
that both TILs-PD-1 and TCs-PD-L1 correlated with OS
and DFS (P < 0.05, Fig. 4a–d) in MSS-proficient subgroup
while neither of TILs-PD-1 and TCs-PD-L1 correlated with
OS or DFS in MSS-deficient subgroup (P > 0.05, Fig. 4e–h).
In the MSS-proficient subgroup, the univariate Cox regres-
sion model revealed that TNM stages, adjuvant chemother-
apy, TILs-PD-1 and TCs-PD-L1 expressions were associated
with prognosis of CRC patients in terms of OS (P < 0.05,
Additional file 1: Table S1), whereas TNM stages, venous
and nervous invasion, pretreatment CEA level, adjuvant
chemotherapy, TILs-PD-1 and TCs-PD-L1 expressions were
associated with prognosis of CRC patients in terms of DFS
(P < 0.05). However, multivariate analysis after adjustment
indicated that only TILs-PD-1 was an independent prognos-
tic factor for OS and only M stage and TILs-PD-1 were in-
dependent prognostic factors for DFS in CRC patients (P <
0.05). In the MSS-deficient subgroup, the Cox regression
model revealed that neither of TILs-PD-1 and TCs-PD-L1
was an independent prognostic factor for OS or DFS in
CRC patients (P > 0.05, Additional file 2: Table S2).
Discussion
PD-1/PD-L1 axis, as an immune checkpoint, is usually
up-regulated to create an immunosuppressive tumor
microenvironment and help cancer cells escape immune-
mediated destruction [20]. Previous studies indicated that
the correlations between PD-L1 and prognosis are variant
among different tumor types [21–24]. For colorectal
cancer, Droeser RA et al. found that PD-L1 expression is
paradoxically associated with improved survival in MMR-
proficient CRC [25]. However, the expression of PD-1 was
not analyzed in their study. Our study aimed at systematic-
ally analyzing the expression of PD-1 and PD-L1 in colo-
rectal cancer cells and tumor infiltrating cells, and their
clinical significance, adopting TCGA database and the
FUSCC cohort of patients. We found that the high expres-
sion of PD-1 or PD-L1 were associated with better prog-
nosis of CRC patients and PD-1 expression in TILs was an
independent prognostic factor for OS and DFS of CRC
patients, specifically for patients in MMR-proficient status.
We firstly used TCGA database to investigate the
relationship between the expression of PD-1/PD-L1 and
clinical outcome. To begin with, X-tile program, a robust
graphic tool, was adopted to identify the optimal cut-off
values of PD-1 and PD-L1 levels. The Kaplan-Meier ana-
lysis revealed the positive correlation of higher PD-1/
PD-L1 expression and better OS of CRC patients, lying
the basis of our study. However, the PD-1/PD-L1 level
in TCGA database was detected by RNA sequencing
Fig. 2 IHC staining of PD-L1 and PD-1 expressions in TMA samples. PD-1 displayed a membrane-accentuated expression, which was often
accompanied by a cytoplasmic expression (b), while PD-L1showed a membrane-accentuated expression (d). Tumor infiltrating lymphocytes
were indicated by red arrows. The representative pictures of negative expression of PD-1/PD-L1 were also shown (a, c)
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Table 2 Univariate and multivariate Cox proportional hazards analysis of OS for patients with CRC in the TCGA cohort
Variablesa Univariate analysis
HR (95 % CI)
Pb Multivariate analysis
HR (95 % CI)
Pb
Age (years)
≤ 60 1.000 0.202 1.000 0.937
> 60 1.366 (0.846–2.204) 1.021 (0.606–1.720)
Gender
Male 1.000 0.132 1.000 0.205








Tis-T2 1.000 <0.001 1.000 <0.001
T3 1.463 (0.618–3.465) 0.832 (0.330–2.053)
T4 8.584 (3.316–22.222) 2.912 (1.242–8.093)
N stage
N0 1.000 <0.001 1.000 0.583
N1 2.311 (1.306–4.091) 1.430 (0.724–2.823)
N2 3.098 (1.718–5.588) 1.213 (0.557–2.642)
M stage
M0 1.000 <0.001 1.000 0.115
M1 4.013 (2.252–7.152) 2.062 (1.007–4.221)
Mx 1.996 (1.083–3.676) 1.701 (0.837–3.458)
Venous invasion
Negative 1.000 0.006 1.000 0.145
Positive 2.411 (1.400–4.151) 2.008 (1.000–4.033)





No. of LNs dissected
< 12 1.000 0.145




MSI 1.159 (0.710–1.892) 0.557
CEA (μl/ml)
≤ 5 1.000 1.000 0.011
> 5 2.146 (0.978–4.708) 0.003 1.339 (0.582–3.081)
Unknown 3.086 (1.617–5.891) 2.778 (1.337–5.772)
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using the whole RNA extracted in tumor tissue quantify-
ing expression level of both TCs and TILs. In fact, PD-1
and PD-L1 are expressed in two tumoral compartments,
tumor cells and TILs respectively, and their interaction
may cause changes in tumor microenvironment, leading
to different results of tumor progression. Thus, TILs-
PD-1 and TCs-PD-L1 were then analyzed separately by
IHC detection based on a relatively large TMA sample
in FUSCC to verify the results in TCGA database.
Consistently, both of the biomarkers were associated
with better OS and DFS of CRC patients.
Currently, the expression of PD-L1 on TCs is
regarded as an immune-tolerance mechanism of the
tumor, as it can attract PD-1 expressing immune-
inhibitory TILs. However, this mechanism is expected
to result into a negative correlation of TILs-PD-1/
TCs-PD-L1 expression and survival, as it was reported,
e.g. for renal cell carcinoma, breast cancer, non-small
cell lung cancer [24] and osteosarcoma [26]. Of note,
the present study is not the only one to report a favor-
able prognostic impact of TILs-PD-1/TCs-PD-L1
expression in cancer cells. Sabatier et al. [22] investi-
gated the PDL1 level in 5, 454 breast cancers using
DNA microarray and demonstrated that higher PDL1
expression was associated with better metastasis-free
survival and OSS and better response to chemother-
apy. Additionally, Darb-Esfahani et al. [27] detected
the PD-1 and PD-L1 protein expression by IHC on
TMA from 215 primary ovary cancers and described
that PD-1 and PD-L1 expression in TCs were positive
prognostic factors for progression-free survival and
OS.
Table 2 Univariate and multivariate Cox proportional hazards analysis of OS for patients with CRC in the TCGA cohort (Continued)
PD-1
Low 1.000 1.000 0.68
High 0.591 (0.364–0.961) 0.034 0.883 (0.488–1.596)
PD-L1
Low 1.000 1.000 0.148
High 0.463 (0.279–0.768) 0.003 0.626 (0.332–1.181)
aAll variables are djusted by Cox proportional hazards models including age, gender, T stage, N stage and M stage
bItalic entries indicate statistical significance
Fig. 3 Kaplan Meier analyses for TILs-PD-1/TCs-PD-L1 expression and their correlation with clinical outcome in FUSCC cohort. a OS according to
TILs-PD-1; b DFS according to TILs-PD-1; c OS according to TCs-PD-L1; d DFS according to TCs-PD-L1
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Table 3 Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in the FUSCC cohort
Variablesa OS DFS
Univariate analysis Pb Multivariate analysis Pb Univariate analysis Pb Multivariate analysis Pb
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Age (years)
≤ 60 1.000 0.367 1.000 0.564 1.000 0.593 1.000 0.633
> 60 1.224 (0.789–1.900) 1.154 (0.709–1.879) 1.115 (0.749–1.661) 1.113 (0.717–1.730)
Genderb
Male 1.000 0.418 1.000 0.493 1.000 0.238 1.000 0.305
Female 0.829 (0.526–1.306) 0.843 (0.518–1.374) 0.781 (0.518–1.178) 0.793 (0.509–1.235)
Tumor location
Colon 1.000 0.061 1.000 0.223
Rectum 0.658 (0.424–1.020) 0.784 (0.529–1.160)
Histological type
Adenocarcinoma 1.000 0.781 1.000 0.765
Mucinous/SRCC 0.867 (0.317–2.369) 0.872 (0.355–2.143)
T stage
Tis-T2 1.000 <0.001 1.000 0.017 1.000 <0.001 1.000 0.032
T3 4.450 (0.975–20.312) 6.329 (1.325–30.238) 2.979 (0.971–9.138) 3.471 (1.074–11.221)
T4 10.534 (2.581–42.992) 8.734 (1.948–39.161) 6.524 (2.390–17.805) 4.282 (1.443–12.710)
N stage
N0 1.000 <0.001 1.000 0.269 1.000 <0.001 1.000 0.089
N1 2.770 (1.537–4.992) 2.011 (0.982–4.117) 2.927 (1.721–4.979) 2.251 (1.202–4.215)
N2 4.146 (2.336–7.357) 1.931 (0.903–4.130) 4.212 (2.510–7.069) 1.968 (0.984–3.934)
M stage
M0 1.000 <0.001 1.000 0.024 1.000 <0.001 1.000 <0.001
M1 9.094 (5.757–14.367) 2.833 (1.137–6.083) 10.198 (6.648–15.642) 4.377 (1.999–9.585)
Pathological grading
Well/moderate 1.000 0.378 1.000 0.729
Poor/anaplastic 1.278 (0.762–2.144) 1.137 (0.706–1.832)
Unknown 0.576 (0.180–1.836) 0.784 (0.317–1.941)
Venous invasion
Negative 1.000 <0.001 1.000 0.987 1.000 <0.001 1.000 0.55
Positive 2.448 (1.578–3.796) 0.986 (0.578–1.681) 2.216 (1.492–3.291) 0.760 (0.464–1.246)










Table 3 Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in the FUSCC cohort (Continued)
Nervous invasion
Negative 1.000 0.059 1.000 0.008 1.000 0.199
Positive 1.641 (0.981–2.743) 1.186 (1.175–2.949) 1.375 (0.846–2.237)
No. of LNs dissected
< 12 1.000 0.249 1.000 0.297
≥ 12 0.719 (0.410–1.260) 0.757 (0.449–1.276)
MMR status
MMR-proficient 1.000 0.726 1.000 0.792
MMR-deficient 1.084 (0.692–1.696) 0.947 (0.632–1.418)
CEA (μl/ml)
≤ 5 1.000 <0.001 1.000 0.041 1.000 <0.001 1.000 0.096
> 5 2.468 (1.572–3.875) 1.386 (0.824–2.331) 2.768 (1.845–4.152) 1.529 (0.956–2.444)
Unknown 2.850 (1.118–7.265) 3.513 (1.292–9.558) 2.472 (0.979–6.246) 2.230 (0.848–5.863)
Adjuvant chemotherapy
Yes 1.000 <0.001 1.000 0.019 1.000 <0.001 1.000 0.366
No 0.670 (0.315–1.425) 1.835 (0.735–4.584) 0.568 (0.281–1.146) 1.419 (0.609–3.307)
Unknown 8.344 (5.142–13.542) 3.130 (1.345–7.282) 6.990 (4.495–10.870) 1.645 (0.755–3.584)
TILs-PD-1
Low 1.000 0.007 1.000 0.006 1.000 0.003 1.000 0.015
High 0.500 (0.302–0.828) 0.480 (0.283–0.814) 0.502 (0.319–0.789) 0.559 (0.350–0.893)
TCs-PD-L1
Low 1.000 0.027 1.000 0.852 1.000 0.005 1.000 0.66
High 0.606 (0.389–0.944) 1.048 (0.639–1.719) 0.558 (0.373–0.835) 0.904 (0.577–1.417)
aAll variables are djusted by Cox proportional hazards models including age, gender, T stage, N stage and M stage










Fig. 4 (See legend on next page.)
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Now, it can only be speculated why the up-regulation of
PD-1/PD-L1 axis are in some instances (such as in CRC
in the present study) referred to a favorable clinical out-
come. A positive impact of PD-L1 expression of TCs
might be explained by a compensatory up-regulation of
this marker in a microenvironment that threatens the
tumor by an active immune response. An association
between TCs-PD-L1 and a high TILs density would be an
argument for this hypothesis, and has been well illustrated
in breast cancer [22, 28]. However this hypothesis remains
speculative. The positive prognostic impact of TILs-PD-1
may also base on regulatory and not yet completely eluci-
dated mechanisms within the immune network in the
tumor microenvironment. Therefore, regulatory and
immune-suppressive T cells might be up-regulated during
an enhanced anti-tumoral immune response.
Previous studies indicated that active immune micro-
environment was observed in MSI/MMR-deficient tumors
[19], and these tumors are characterized by a more favor-
able prognosis compared to MSS/MMR-proficient tu-
mors. MSI is typically diagnosed by the variable lengths of
DNA microsatellites (mononucleotide and dinucleotide
repeats), which is caused by epigenetic silencing or muta-
tion of DNA MMR genes, leading to accumulated muta-
tions at 10–100 times the normal rate and promotes MSI
carcinoma progression [19]. In the MSI/MMR-deficient
subset of CRC, the high accumulated mutation creates
many tumor-specific neoantigens, typically 10–50 times
that of MSS/MMR-proficient subset [29], which might be
the reason for the high level of TILs and active Th1/CTL
immune microenvironment in MSI/MMR-tumors ob-
served in many previous studies [19]. In the present study,
subgroup analyses were carried out in FUSCC cohort and
demonstrated that higher expressions of TILs-PD-1 and
TCs-PD-L1 were associated with better prognosis in
MMR-proficient subgroup while no correlation was found
between TILs-PD-1/TCs-PD-L1 expression and progno-
sis. Surprisingly, TILs-PD-1 was even an independent fac-
tor for OS and DFS of CRC patients. The underline
mechanisms remain unclear. IFN-γ, mainly produced by
activated infiltrating T cells, has been reported to be asso-
ciated with a favorable prognosis [30] and has been shown
to promote the expression of PD-1 ligands in different
cell types, which might mirror the co-overexpression
of TILs-PD-1 and TCs-PD-L1 in MMR-proficient
CRC. In the present study, among 356 eligible pa-
tients included in TCGA database, 250 patients have
the data of IFN-γ gene expression. Spearman test
showed that both PD-1 and PDL-1 are highly directly
correlated with IFN-γ with r = 0.7285 (P < 0.0001,
95 % CI: 0.6624–0.7833) and r = 0.7475 (P < 0.0001,
95 % CI: 0.6853–0.7990), which supported the above
hypothesis (Additional file 3: Figure S1). On the other
hand, the intestinal immune system is shaped by a con-
tinuous interaction with commensal microbiota [31].
Possibly, as a consequence of this specific microenvir-
onment, CRC infiltration by immunocompetent cells is
associated with paradoxically peculiar features [32]. In-
deed, previous studies [33] demonstrated that, in contrast
to a wide range of human cancers, CRC infiltration by
FOXP3+ regulatory T cells, is associated with an improved
prognosis. Furthermore, it has also been observed that
CRC infiltration by myeloid cells is also associated with a
favorable prognosis [34].
To our knowledge, the present study is the first study
based on East Asia patients concerning PD-1 and PD-L1
analyses, which combines TCGA database and center-
based cohort to comprehensively and specifically investigate
TILs-PD-1 and TCs-PD-L1 and their clinical relevance in
CRC. However, our study has several limitations. First, the
insufficient data on recurrence in CRC patients from in
TCGA database limited the analyses on the impact of PD-
1/PD-L1 expression for DFS. And the TCGA database does
not include information regarding the pathological grading,
nervous invasion and administration of chemotherapy and
all these factors may affect the multivariate analysis of
TCGA data. Secondly, although we have analyzed a large
cohort, the present study is a retrospective analysis and
there is a potential for selection bias. A relatively small sam-
ple of the MMR-deficient subgroup may result in lack of
power for the Cox regression analysis and some of potential
correlation between TILs-PD-1/TCs-PD-L1 expression and
clinical outcome may fail to manifest. Thirdly, it is difficult
to compare the results from our study with previous studies
due to different antibodies and variant methodologies used
to evaluate TILs-PD-1/TCs-PD-L1 expression.
Conclusion
In conclusion, higher expression of PD-1 and PD-L1 is
associated with better prognosis of CRC patients in
TCGA and FUSCC cohort. TILs-PD-1 expression was
an independent prognostic factor for OS and DFS of
CRC patients, especially for MMR-proficient tumors.
(See figure on previous page.)
Fig. 4 Subgroup analyses using Kaplan Meier method for TILs-PD-1/TCs-PD-L1 expression and their correlation with clinical outcome in FUSCC
cohort. a OS according to TILs-PD-1 in MMR-proficient subgroup; b OS according to TCs-PD-L1 in MMR-proficient subgroup; c DFS according to
TILs-PD-1 in MMR-proficient subgroup; d DFS according to TCs-PD-L1 in MMR-proficient subgroup; e OS according to TILs-PD-1 in MMR-deficient
subgroup; f OS according to TCs-PD-L1 in MMR-deficient subgroup; g DFS according to TILs-PD-1 in MMR-deficient subgroup; h DFS according
to TCs-PD-L1 in MMR-deficient subgroup
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Future investigations should focus on PD-1/PD-L1
expression on TILs, instead of only on TCs.
Additional files
Additional file 1: Table S1. Univariate and multivariate Cox
proportional hazards analysis of OS and DFS for patients with CRC in
MMR-proficient subgroup of the FUSCC cohort. (DOCX 18 kb)
Additional file 2: Table S2. Univariate and multivariate Cox
proportional hazards analysis of OS and DFS for patients with CRC in
MMR-deficient subgroup of the FUSCC cohort. (DOCX 17 kb)
Additional file 3: Figure S1. Correlation of PD-1/PD-L1 and IFN-γ in
TCGA database. In TCGA cohort, 250 patients have the data of IFN-γ
gene expression. Spearman test was used to determine the correlation of
PD-1/PD-L1 and IFN-γ. (a) The expression of PD-1 is directly correlated with
IFN-γ (P < 0.0001, r = 0.7285, 95 % CI: 0.6624–0.7833). (b) The expression of
PD-L1 is directly correlated with IFN-γ (P < 0.0001, r = 0.7475, 95 % CI:
0.6853–0.7990). (TIF 1066 kb)
Acknowledgements
The authors acknowledge the efforts of The Cancer Genome Atlas in the
creation of the database. The interpretation and reporting of these data are
the sole responsibility of the authors.
Funding
This work was supported by the National Natural Science Foundation of
China (Grant No. 81372646, 81101586) and National Key Basic Research
Program of China (2014CBA02002).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article and its additional files.
Authors’ contributions
XL and QL conceived this study. GC and YX improved the study design and
contributed to the interpretation of results. YL and WD performed IHC
staining. LL performed data processing and statistical analysis. QL and YL
wrote the manuscript. SC revised the manuscript and approved the final
version. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
TMA was constructed with materials collected from Tissue Bank of FUSCC
and this institution is allowed to perform translational research with the
approval of the Ethical Committee and Institutional Review Board of FUSCC
in compliance with ethical standards and patient confidentiality.
Author details
1Department of Colorectal Surgery, Fudan University Shanghai Cancer
Center, 270 Dong’an Road, Shanghai 20032, China. 2Department of
Oncology, Shanghai Medical College, Fudan University, 270 Dong’an Road,
Shanghai 20032, China.
Received: 31 May 2016 Accepted: 15 August 2016
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF,
Powderly JD. Safety, activity, and immune correlates of anti–PD-1 antibody
in cancer. N Engl J Med. 2012;366:2443–54.
3. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is
a particularly good candidate for checkpoint blockade immunotherapy.
Cancer Discov. 2015;5:16–8.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagés C.
Type, density, and location of immune cells within human colorectal
tumors predict clinical outcome. Science. 2006;313:1960–4.
5. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of
T-cell immunity. Nat Rev Immunol. 2004;4:336–47.
6. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I,
Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1
and inhibits T cell activation. Nat Immuol. 2001;2:261–8.
7. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda
M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1
mediates peripheral T cell tolerance. J Exp Med. 2006;203:883–95.
8. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance
and immunity. Annu Rev Immunol. 2008;26:677–704.
9. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance.
Trends Immunol. 2006;27:195–201.
10. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA,
McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of
response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature.
2014;515:563–7.
11. Awad MM, Hammerman PS. Durable responses with PD-1 inhibition in lung
and kidney cancer and the ongoing search for predictive biomarkers. J Clin
Oncol. 2015;33:1993–4.
12. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris
HA, Petrylak DP, Teng SL, et al. MPDL3280A (anti-PD-L1) treatment leads to
clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62.
13. Jiang YZ, Yu KD, Zuo WJ, Peng WT, Shao ZM. GATA3 mutations define a
unique subtype of luminal-like breast cancer with improved survival. Cancer.
2014;120:1329–37.
14. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev
Drug Discov. 2003;2:962–72.
15. Cancer Genome Atlas N. Comprehensive molecular characterization of
human colon and rectal cancer. Nature. 2012;487:330–7.
16. Lugli A, Zlobec I, Baker K, Minoo P, Tornillo L, Terracciano L, Jass JR.
Prognostic significance of mucins in colorectal cancer with different DNA
mismatch-repair status. J Clin Pathol. 2007;60:534–9.
17. Baker K, Zlobec I, Tornillo L, Terracciano L, Jass JR, Lugli A. Differential
significance of tumour infiltrating lymphocytes in sporadic mismatch repair
deficient versus proficient colorectal cancers: a potential role for
dysregulation of the transforming growth factor-beta pathway. Eur J Cancer.
2007;43:624–31.
18. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a New Bio-informatics tool for
biomarker assessment and outcome-based Cut-point optimization. Clin
Cancer Res. 2004;10:7252–9.
19. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker
for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22.
20. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer
immunotherapy. Mol Cancer Ther. 2015;14:847–56.
21. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J,
Carvo I, Lampron M, et al. PD-L1 expression in nonclear-cell renal cell
carcinoma. Ann Oncol. 2014;25:2178–84.
22. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm
DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs
and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773–82.
23. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-
ligand 1 expression is associated with a favourable immune
microenvironment and better overall survival in stage I pulmonary
squamous cell carcinoma. Eur J Cancer. 2016;57:91–103.
24. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J,
Liang W. Prognostic significance of programmed cell death 1 (PD-1) or PD-1
ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis.
Medicine (Baltimore). 2015;94:e515.
25. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I,
Eppenberger-Castori S, Tzankov A, Rosso R, et al. Clinical impact of
programmed cell death ligand 1 expression in colorectal cancer. Eur J
Cancer. 2013;49:2233–42.
26. Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination
immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade
Li et al. Molecular Cancer  (2016) 15:55 Page 14 of 15
prevents immune escape and leads to complete control of metastatic
osteosarcoma. J Immunother Cancer. 2015;3:21.
27. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J,
Bockmayr M, Dietel M, Denkert C, Braicu I, JÖhrens K. Prognostic impact of
programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in
cancer cells and tumor-infiltrating lymphocytes in ovarian high grade
serous carcinoma. Oncotarget. 2016;7:1486–99.
28. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali H, Viens P,
Caldas C, Brinbaum D, Bertucci F. Prognostic and predictive value of PDL1
expression in breast cancer. Oncotarget. 2015;6:5449–64.
29. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser
RL, Fan H, Wang H, Luber BS, et al. The vigorous immune
microenvironment of microsatellite instable colon cancer is balanced by
multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.
30. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B,
Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early
metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.
31. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the
gut microbiome and the immune system. Nature. 2011;474:327–36.
32. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory
T cells infiltrating human carcinomas- the paradox of colorectal cancer.
Cancer Immunol Immunother. 2011;60:909–18.
33. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta
B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.
34. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E,
Patsouris ES, Peros G, Horcic M, Tornillo L, et al. Tumor infiltration by
FcgammaRIII (CD16) + myeloid cells is associated with improved survival in
patients with colorectal carcinoma. Int J Cancer. 2011;128:2663–72.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. Molecular Cancer  (2016) 15:55 Page 15 of 15
